A Chinese medicine composition and its application in preparing medicine for preventing and treating colon adenoma

By preparing the traditional Chinese medicine compositions Snake Liugu, Banzhiliu, Vines, Pear Root, Coix seed, black plum and white cardamom, the problem of high recurrence rate of colorectal adenoma is solved, and the inhibition of colorectal adenoma growth and intestinal tract are achieved. Overall improvement of health.

CN117045758BActive Publication Date: 2024-11-05HUZHOU CENT HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311032274.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-08-16
Publication Date
2024-11-05
Estimated Expiration
2043-08-16

AI Technical Summary

Technical Problem

The recurrence rate of colorectal adenomas is high, and Western medicine lacks effective preventive and therapeutic drugs, which leads to patients facing serious health risks.

Method used

A Chinese medicine composition is adopted, including Snake Liugu, Banzhiliu, Vines, Pear Root, Coix seed, Black Plum and White Cardamom, and the dosage forms such as decoction, tablets, granules, capsules, pills, ointments, etc., according to specific dosage forms Proportional formulation for inhibiting colon adenoma growth and preventing recurrence.

Benefits of technology

Significantly inhibit the growth of colon adenomas, reduce the number and volume of adenomas, improve the structure of the intestinal glands, reduce inflammatory response, improve the function of the intestinal mucosal barrier, regulate intestinal flora, and affect bile acid metabolism, thereby effectively preventing and treating colorectal adenomas development and recurrence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117045758B_ABST
    Figure CN117045758B_ABST
Patent Text Reader

Abstract

The invention belongs to the field of traditional Chinese medicine, and relates to a traditional Chinese medicine composition for preventing and treating colorectal adenoma, wherein the traditional Chinese medicine composition comprises 20-40 parts of herba schizonepetae, 20-40 parts of herba schizonepetae, 20-40 parts of herba schizonepetae, 20-40 parts of herba schizonepetae, 10-20 parts of herba schizonepetae, and 5-15 parts of herba schizonepetae. The traditional Chinese medicine composition uses six kinds of drugs together, has less raw material taste, low cost, can effectively inhibit or slow down the growth of colon adenoma, and the traditional Chinese medicine composition has good effects of preventing and treating the development of colorectal adenoma, canceration and postoperative recurrence of colorectal adenoma through animal experiments.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition and application thereof in preparing a medicine for preventing and treating colon adenoma. Background Art

[0002] Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies. Colorectal adenomas originate from benign tumors of the colorectal mucosa. They are protruding lesions that protrude from the mucosa into the intestinal cavity. They are benign epithelial tumors of the intestine and the main precancerous lesions of colorectal cancer. More than 90% of intestinal cancers develop from intestinal adenomas. Resection of adenomas after endoscopic screening is currently the most effective prevention strategy, which can reduce the morbidity and mortality associated with CRC. However, recurrence after endoscopic resection of intestinal adenomas is a very common clinical phenomenon, with an annual recurrence rate of up to 10%-15%, which causes great physical and mental damage to patients. Western medicine does not have effective targeted drugs for further prevention and treatment. Therefore, it is of great significance to study effective prevention and treatment strategies and find safe and effective drugs for the prevention and treatment of colorectal adenomas to reduce the recurrence of colorectal adenomas and the incidence of colorectal cancer. Summary of the invention

[0003] In view of the current technical problems, the purpose of the present invention is to provide a Chinese medicine composition, the use of which can effectively inhibit or slow down the growth of colon adenomas and has a good effect in preventing the recurrence of colorectal adenomas after surgery.

[0004] To achieve the above object, the present invention provides the following technical solutions:

[0005] On the one hand, the present invention provides a traditional Chinese medicine composition, which includes herba epimedii, herba barbata, herba ramie roots, coix seeds, black plums, and white cardamom. The weight proportions of the herba epimedii are: 20-40 parts of herba epimedii, 20-40 parts of herba barbata, 20-40 parts of herba ramie roots, 20-40 parts of coix seeds, 10-20 parts of black plums, and 5-15 parts of white cardamom.

[0006] Preferably, the weight proportions of the Chinese medicine composition are: 25-35 parts of Herba Epimedii, 25-35 parts of Scutellariae Barbatae, 25-35 parts of Rhizoma Cibotii, 25-35 parts of Semen Coicis, 13-17 parts of Prunus mume, and 8-12 parts of Amomum villosum.

[0007] In some specific embodiments, the weight proportions of the Chinese medicine composition are: 30 parts of Herba Epimedii, 30 parts of Scutellariae Barbatae, 30 parts of Rhizoma Cibotii, 30 parts of Semen Coicis, 15 parts of Prunus mume, and 10 parts of Radix Cardamomum.

[0008] Furthermore, the dosage form of the Chinese medicine composition is decoction, tablet, granule, capsule, pill, ointment. The method of taking is two doses per day, morning and evening.

[0009] The second aspect of the present invention provides a use of a traditional Chinese medicine composition in the preparation of a medicament for preventing colorectal adenoma.

[0010] The third aspect of the present invention provides a use of a traditional Chinese medicine composition in the preparation of a medicament for treating colorectal adenoma.

[0011] A fourth aspect of the present invention provides use of a traditional Chinese medicine composition in the preparation of a medicament for preventing postoperative recurrence of colorectal adenoma.

[0012] Furthermore, the drug is used to achieve one or more of the following effects:

[0013] (1) Prevent the recurrence of intestinal adenoma;

[0014] (2) Reduce the number and size of intestinal adenomas;

[0015] (3) Improve intestinal gland structural abnormalities;

[0016] (4) Inhibit abnormal proliferation of intestinal epithelial cells;

[0017] (5) Reduce intestinal and systemic inflammatory responses;

[0018] (6) Improve intestinal mucosal barrier function;

[0019] (7) Reshape the intestinal flora;

[0020] (8) Changes in bile acid metabolism.

[0021] Traditional Chinese medicine attributes colorectal adenoma to "accumulation", "intestinal wind" and "intestinal fungus". The Chinese medicine prescription of the present invention is carefully selected under the guidance of many years of clinical experience and traditional Chinese medicine theory. The snake six grains in the prescription are also called black taro, ghost candle, ghost konjac, ghost head, single leaf flower, star taro, and Tianliugu. They are the tubers of the Araceae plant konjac and have certain toxicity; the snake six grains are pungent and warm in nature; they enter the lung, liver, and spleen meridians; they have the effects of resolving phlegm and dispersing accumulation, promoting blood stasis and reducing swelling; the snake six grains in this prescription are the main medicine for resolving phlegm and dispersing nodules.

[0022] Scutellaria barbata tastes pungent and bitter, and is cold in nature. It enters the lung, liver, and kidney meridians, and its main functions are clearing away heat and detoxification, removing blood stasis and stopping bleeding, and diuresis and swelling. The root of vine pear comes from the dried root of the plant Actinidia arguta of the Actinidia family. Its nature and flavor are light, slightly astringent, and flat; its efficacy and function are clearing away heat and dampness, dispelling wind and removing numbness, detoxification, swelling, and hemostasis. In this prescription, Scutellaria barbata and root of vine pear are the ministerial drugs for clearing away heat and detoxification, removing dampness and swelling.

[0023] Coix seeds are sweet, light, and cool in nature. They are used in the spleen, stomach, and lung meridians. They have the effects of promoting water and penetrating dampness, strengthening the spleen and stopping diarrhea, removing numbness, discharging pus, and detoxifying and dispersing knots. Plums are sour, astringent, and neutral in nature. They are used in the liver, spleen, lung, and large intestine meridians. They have the effects of astringing the lungs and stopping coughs, astringing the intestines and stopping diarrhea, calming ascariasis and stopping pain, and promoting body fluids and quenching thirst. Coix seeds and plums are used as adjuvants in this recipe.

[0024] White cardamom is pungent and warm in nature. It enters the lung, spleen and stomach meridians and has the effects of removing dampness and promoting qi, warming the middle and stopping vomiting, and stimulating appetite and digestion. It is mainly used to treat dampness blocking qi stagnation, spleen and stomach disharmony, abdominal distension, loss of appetite, initial onset of damp-heat, chest tightness without hunger, stomach cold and vomiting, and indigestion. In this prescription, white cardamom is used as a guiding drug to regulate qi and remove dampness.

[0025] The Chinese medicine composition comprises six drugs which are used together to resolve phlegm and dissipate stagnation, clear away heat and detoxify, promote dampness and reduce swelling, consolidate the intestine and stop diarrhea, strengthen the spleen and eliminate dampness, warm the middle and promote the circulation of qi, and can effectively inhibit or slow down the growth of colon adenoma. Animal experiments have verified that the Chinese medicine composition has good effects in preventing and treating the development and canceration of colorectal adenoma and the recurrence of colorectal adenoma after surgery.

[0026] Beneficial effects of the present invention

[0027] The present invention has the following beneficial effects: the Chinese medicine composition of the present invention has a significant inhibitory effect on the growth of adenoma, can effectively reduce the number and volume of adenoma, and improve the abnormal structure of intestinal glands. At the same time, the Chinese medicine composition also shows improvement in the permeability of the intestinal mucosal barrier, inhibition of abnormal proliferation of glandular epithelial cells, reduction of intestinal and systemic inflammatory responses, and improvement of the quality of life. It can reshape the intestinal flora and regulate specific intestinal flora to affect bile acid metabolism, thereby affecting the occurrence and development of intestinal adenomas.

[0028] The Chinese medicine composition of the present invention selects 6 kinds of Chinese medicine ingredients, the raw materials have less medicinal taste and low cost; according to the dosage ratio in the prescription, the medicine can be decocted in water or directly prepared using Chinese medicine granules that do not require decocting, the preparation is simple, and it is convenient for popularization and use. The Chinese medicine composition has a significant inhibitory effect on the growth of the number and volume of intestinal adenomas, and has a good effect on preventing and treating the development and canceration of colorectal adenomas and the postoperative recurrence of colorectal adenomas. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 To investigate the effect of Chinese medicine intervention on the body weight of mice with adenoma;

[0030] Figure 2 To investigate the effect of Chinese medicine intervention on the occurrence and development of intestinal adenoma in mice;

[0031] Figure 3 The intervention of traditional Chinese medicine inhibited the pathological progression of intestinal adenoma tissue in mice;

[0032] Figure 4 The intervention of traditional Chinese medicine inhibited the abnormal proliferation of intestinal epithelial tissue in mice;

[0033] Figure 5 To investigate the effect of traditional Chinese medicine intervention on the expression of inflammation-related proteins in intestinal adenoma of mice;

[0034] Figure 6The changes of serum inflammatory factors in adenoma mice after Chinese medicine intervention;

[0035] Figure 7 To improve the intestinal mucosal barrier function of adenoma mice by Chinese medicine intervention;

[0036] Figure 8 To regulate the structure and composition of intestinal flora in mice with adenoma through intervention with traditional Chinese medicine;

[0037] Fig. 9 To analyze the correlation between the intestinal flora differences and the number of intestinal adenomas in mice with adenoma after Chinese medicine intervention;

[0038] Fig.10 To investigate the effect of Chinese medicine intervention on intestinal bacteria-related metabolites in feces of mice with adenoma;

[0039] Fig.11 This is a correlation analysis between fecal metabolites and intestinal flora and the number of intestinal adenomas in mice. DETAILED DESCRIPTION

[0040] Unless otherwise indicated, implied from the context, or customary in the prior art, all parts and percentages in this application are based on weight, and the test and characterization methods used are all current as of the filing date of this application. Where applicable, the contents of any patent, patent application or publication referred to in this application are fully incorporated herein by reference, and their equivalent patent families are also incorporated by reference, especially the definitions of synthesis techniques, product and processing designs, polymers, comonomers, initiators or catalysts disclosed in these documents in the art. If the definition of a specific term disclosed in the prior art is inconsistent with any definition provided in this application, the definition of the term provided in this application shall prevail.

[0041] The numerical ranges in this application are approximate values, so unless otherwise specified, they may include values ​​outside the range. Numerical ranges include all values ​​from the lower limit to the upper limit increased by 1 unit, provided that there is an interval of at least 2 units between any lower value and any higher value. For example, if the recorded component, physical or other properties (such as molecular weight, melt index, etc.) are 100 to 1000, it means that all single values ​​are clearly listed, such as 100, 101, 102, etc., and all sub-ranges, such as 100 to 166, 155 to 170, 198 to 200, etc. For a range containing a value less than 1 or containing a fraction greater than 1 (such as 1.1, 1.5, etc.), 1 unit is appropriately regarded as 0.0001, 0.001, 0.01 or 0.1. For a range containing a single digit less than 10 (such as 1 to 5), 1 unit is usually regarded as 0.1. These are only specific examples of what is intended, and all possible combinations of numerical values ​​between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application.

[0042] When used with respect to chemical compounds, unless expressly specified otherwise, the singular includes all isomeric forms and vice versa (e.g., "hexane" includes all isomers of hexane, individually or collectively). In addition, nouns using "a," "an," or "the" also include their plural forms unless expressly specified otherwise.

[0043] The terms "comprising", "including", "having" and their derivatives do not exclude the presence of any other components, steps or processes, and are irrelevant to whether these other components, steps or processes are disclosed in this application. To eliminate any doubt, unless explicitly stated, all compositions using the terms "comprising", "including", or "having" in this application may include any additional additives, adjuvants or compounds. On the contrary, except for those necessary for operating performance, the term "essentially consisting of..." excludes any other components, steps or processes from the scope of any description of the term below. The term "consisting of..." does not include any components, steps or processes that are not specifically described or listed. Unless explicitly stated, the term "or" refers to the listed individual members or any combination thereof.

[0044] In order to make the technical problems, technical solutions and beneficial effects solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments.

[0045] Example

[0046] The following examples are used to demonstrate preferred embodiments of the present invention. It will be appreciated by those skilled in the art that the techniques disclosed in the following examples represent techniques discovered by the inventors that can be used to implement the present invention and therefore can be considered as preferred embodiments of the present invention. However, it will be appreciated by those skilled in the art based on this specification that many modifications may be made to the specific embodiments disclosed herein and still achieve the same or similar results without departing from the spirit or scope of the present invention.

[0047] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs, and the disclosure and materials cited therein are hereby incorporated by reference.

[0048] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many technical equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the claims.

[0049] Example 1

[0050] A Chinese medicine preparation for preventing and treating colorectal adenoma and reducing the recurrence of colorectal adenoma comprises the following raw materials in parts by weight: 18 parts of Herba Scutellariae, 28 parts of Scutellariae Scutellariae, 40 parts of Rhizoma Cibotii, 25 parts of Semen Coix, 13 parts of Prunus mume, and 8 parts of Cardamomum villosum. The above raw materials are crushed into powder with a particle size of 30-100 microns, cellulose and starch are added to the powder, and then tablets are pressed to prepare tablets, which are sterilized by irradiation to prepare tablets.

[0051] Example 2

[0052] A Chinese medicine preparation for preventing and treating colorectal adenoma and reducing the recurrence of colorectal adenoma comprises the following raw materials in parts by weight: 32 parts of Herba Scutellariae, 25 parts of Scutellariae Scutellariae, 25 parts of Rhizoma Cibotii, 40 parts of Semen Coix Lachryma-jobi, 10 parts of Prunus mume, and 12 parts of Cardamomum villosum. The above raw materials are crushed into powder with a particle size of 30-100 microns, the powder is put into capsules, and the capsules are sterilized by irradiation to form capsules.

[0053] Example 3

[0054] A Chinese medicine preparation for preventing and treating colorectal adenoma and reducing the recurrence of colorectal adenoma comprises the following raw materials in parts by weight: 20 parts of Herba Scutellariae, 40 parts of Scutellariae Scutellariae, 20 parts of Rhizoma Cibotii, 35 parts of Semen Coix, 17 parts of Prunus mume, and 15 parts of Cardamomum villosum. The above raw materials are combined, and water is added successively to heat and boil to extract for multiple times, and the extracts are filtered, combined, and bagged to obtain a decoction.

[0055] Example 4

[0056] A Chinese medicine preparation for preventing and treating colorectal adenoma and reducing the recurrence of colorectal adenoma comprises the following raw materials in parts by weight: 30 parts of Herba Scutellariae, 30 parts of Scutellariae Scutellariae, 30 parts of Rhizoma Coix, 30 parts of Semen Coicis, 15 parts of Prunus mume, and 10 parts of Cardamomum villosum. The above raw materials are combined, ethanol is added for reflux extraction for multiple times, the extracts are filtered, combined and concentrated to an appropriate volume, spray dried and bagged to obtain granules.

[0057] Example 5

[0058] A Chinese medicine preparation for preventing and treating colorectal adenoma and reducing the recurrence of colorectal adenoma comprises the following raw materials in parts by weight: 40 parts of Herba Scutellariae, 20 parts of Scutellariae Scutellariae, 35 parts of Rhizoma Cibotii, 20 parts of Semen Coix Lachryma-jobi, 20 parts of Prunus mume, and 5 parts of Cardamomum villosum. The above raw materials are combined, ethanol is added for reflux extraction for multiple times, the extracts are filtered, combined and concentrated to an appropriate concentration, and then bottled to obtain an ointment.

[0059] Example 6

[0060] APC in the C57BL / 6J genetic background Min/+ The APC mouse is the most classic intestinal adenoma model mouse. This mouse has the characteristic of spontaneously forming multiple intestinal adenomas under APC gene mutation and is currently recognized as an ideal mouse model for studying adenomatous polyposis.

[0061] 1. Animal: APC Min/+ Seven mice, all four weeks old, were randomly selected according to their body weight and adaptively raised for one week to form a high-dose Chinese medicine group (TCM-H).

[0062] 2. Diet: Provide normal feed and drinking water, and record diet and drinking water twice a week.

[0063] 3. Preparation method of the high-dose group (TCM-H) Chinese medicine composition: The decoction-free granules of Jiangyin Tianjiang Pharmaceutical Co., Ltd. were used. The equivalent ratio of granules to slices (granules / slices) was 1.5 / 15 for Herba Scutellariae, 1 / 15 for Scutellariae Scutellariae, 0.5 / 15 for Rhizoma Cibotii, 0.5 / 10 for Rhizoma Coix, 3 / 10 for Prunus Mume, and 0.5 / 3 for Rhizoma Cibotii. According to the dosage conversion ratio of 12.1:1 for mice and humans, 450 mg of Herba Scutellariae, 300 mg of Scutellariae Scutellariae, 150 mg of Rhizoma Cibotii, 225 mg of Prunus Mume, and 250 mg of Rhizoma Cibotii were dissolved in 10 ml of sterile double-distilled water.

[0064] 4. Administration method: daily oral administration, dosage: 0.1 mL / 10 g, that is, for every 10 g of mouse body weight, 0.1 ml of the high-dose Chinese medicine composition is administered by oral administration.

[0065] 5. Experimental period: 12 weeks.

[0066] 6. Observation indicators:

[0067] 6.1. Weight and health status;

[0068] 6.2. Number and size of adenomas in the small intestine and colorectum;

[0069] 6.3 Histopathology of intestinal adenoma;

[0070] 6.4. Expression of genes related to intestinal adenoma cell proliferation and inflammation;

[0071] 6.5. Levels of serum inflammatory factors;

[0072] 6.6. Intestinal barrier function;

[0073] 6.7. Composition and structure of intestinal flora;

[0074] 6.8. Correlation analysis between changes in intestinal flora and the number of adenomas;

[0075] 6.9. Intestinal flora-related metabolites;

[0076] 6.10. Correlation between fecal metabolites and intestinal flora and the number of intestinal adenomas.

[0077] Example 7

[0078] The mouse model used was the same as that in Example 6.

[0079] 1. Animal: APC Min/+ Seven mice, all four weeks old, were randomly selected according to their body weight and adaptively raised for one week to form a low-dose Chinese medicine group (TCM-L).

[0080] 2. Diet: Provide normal feed and drinking water, and record diet and drinking water twice a week.

[0081] 3. Preparation method of Chinese medicine composition in low-dose group (TCM-L): The Chinese medicine decoction-free granules produced by Jiangyin Tianjiang Pharmaceutical Co., Ltd. were used. The equivalent ratio of granules to slices (granules / slices) was 1.5 / 15 for Herba Scutellariae, 1 / 15 for Scutellariae Scutellariae, 0.5 / 15 for Rhizoma Cibotii, 0.5 / 10 for Rhizoma Coix, 3 / 10 for Plum, and 0.5 / 3 for Plum. According to the dosage conversion ratio of 12.1:1 for mice and humans, 225 mg of Herba Scutellariae, 150 mg of Scutellariae Scutellariae, 75 mg of Rhizoma Cibotii, 112.5 mg of Plum, 337.5 mg of Plum, and 125 mg of Plum were dissolved in 10 ml of water.

[0082] 4. Administration method: daily oral administration, dosage: 0.1 mL / 10 g, that is, for every 10 g of mouse body weight, 0.1 ml of the low-dose Chinese medicine composition is administered by oral administration.

[0083] 5. Experimental period: 12 weeks.

[0084] 6. The observation indexes are the same as those in Example 6.

[0085] Comparative Example 1

[0086] 1. Animals: Five wild-type mice with the same living background as the model mice in Example 6 were randomly selected according to body weight, all of which were four weeks old and adaptively raised for one week to form a blank control group (control).

[0087] 2. Diet: Provide normal feed and drinking water, and record diet and drinking water twice a week.

[0088] 3. Experimental period: 12 weeks.

[0089] 4. The observation indexes are the same as those in Example 6.

[0090] Comparative Example 2

[0091] The mouse model used was the same as that in Example 6.

[0092] 1. Animal: APC Min/+ Seven mice, all four weeks old, were randomly selected according to their body weight and adaptively raised for one week to form the model group (Model).

[0093] 2. Diet: Provide normal feed and drinking water, and record diet and drinking water twice a week.

[0094] 3. Administration and administration method: Daily oral administration of physiological saline, dosage: 0.1 mL / 10 g, that is, for every 10 g of mouse body weight, 0.1 ml of the high-dose Chinese medicine composition was administered by oral administration.

[0095] 4. Experimental period: 12 weeks.

[0096] 5. The observation indexes are the same as those in Example 6.

[0097] Comparative Example 3

[0098] The mouse model used was the same as that in Example 6.

[0099] 1. Animal: APC Min/+ Seven mice, all four weeks old, were randomly selected according to their body weight and adaptively raised for one week to form the berberine group (BBP).

[0100] 2. Diet: Provide normal feed and drinking water, and record diet and drinking water twice a week.

[0101] 3. Administration and administration method: The concentration of berberine is 500 mg / ml. Berberine is administered by intragastric administration every day, the dosage is 0.1 mL / 10 g, that is, 0.1 ml of berberine is administered by intragastric administration for every 10 g of mouse body weight.

[0102] 4. Experimental period: 12 weeks.

[0103] 5. The observation indexes are the same as those in Example 6.

[0104] Experimental Results

[0105] 1. Apc Min/+ Mouse weight and health status

[0106] During the 12-week experimental period, the conditions of the experimental mice were recorded and their body weights were measured at a fixed time each week.

[0107] The results showed that in the fourth week after the experiment, mice in the model group had intermittent bloody stools. In the sixth week, mice in all groups had bloody stools. In the eighth week, it was found that the bloody stools of mice in the model group were particularly serious. The mice in the high-dose group of Chinese medicine intervention were better than those in the low-dose group. In the tenth week, two mice in the model group died, and no mice died in the high- and low-dose groups of Chinese medicine intervention. In the twelfth week, there was no significant difference in the weight of mice in each group. The test results are as follows: Figure 1 shown.

[0108] 2. Apc Min/+ Development of intestinal adenomas in mice

[0109] The experimental mice were dissected and the number and size of adenomas in the small intestine and colorectum were counted.

[0110] The results showed that intestinal adenomas were observed in both the large and small intestines of mice, with multiple lesions in the small intestine.

[0111] Compared with the model group, the number of intestinal adenomas in the low-dose and high-dose groups of Chinese medicine intervention was significantly reduced, and the growth was slowed down (P<0.05), among which the effect of the high-dose group was more significant (P<0.05). The results of Chinese medicine inhibiting the occurrence and development of intestinal adenomas in mice are as follows Figure 2 shown.

[0112] 3. Apc Min/+ Histopathological changes of intestinal adenoma in mice

[0113] HE staining was used to detect the pathological changes of intestinal tissues of mice.

[0114] The results showed that the adenomas in the intestinal tissue of the mice in the model group showed dark nuclear staining, increased nuclear-cytoplasmic ratio, abnormal crypt development, and a large number of proliferating cells and lymphocytes infiltrated. However, in response to these changes, the mice in the drug-treated group showed significant improvement, especially the mice in the high-dose Chinese medicine intervention group had normal intestinal glandular structure, clear mucosal layer structure, no mucosal ulcers, and no obvious dysplasia of glandular epithelial cells; Figure 3 As shown, this suggests that the Chinese medicine prescription can inhibit the histopathological progression of intestinal adenoma in mice.

[0115] 4. Apc Min/+Proliferation and expression of inflammatory factors in mouse intestinal adenoma cells

[0116] Immunofluorescence staining was used to detect β-catenin and Ki-67 in mouse intestinal adenomas to explore whether the efficacy of traditional Chinese medicine is related to its antiproliferative properties.

[0117] The results showed that the expression of β-catenin and Ki-67 in the intestinal adenoma of mice in the Chinese medicine intervention group was significantly reduced (P<0.05). Figure 4 As shown in the figure, inflammation is one of the key factors in tumorigenesis and is related to cancer. Similarly, we also detected the expression of intestinal adenoma inflammation-related proteins ARG1, iNOS and COX-2 in the small intestine of mice. The results showed that compared with the model group, the iNOS, COX-2 and Arg1 protein levels of mice in the Chinese medicine intervention group were significantly reduced (P<0.05). The results of Chinese medicine inhibiting the expression of intestinal adenoma inflammation-related proteins in mice are shown in the figure. Figure 5 shown.

[0118] 5. Apc Min/+ Changes of serum inflammatory factors in mice

[0119] Luminex liquid phase chip was used to detect the expression of 23 inflammatory factors in mouse serum to evaluate whether Chinese medicine intervention can regulate systemic inflammation.

[0120] The results showed that Chinese medicine intervention could significantly increase the levels of cytokines Eotaxin (P<0.05) and IL-12P40 (P<0.001), and significantly reduce the level of RANTES (P<0.05). Figure 6 shown.

[0121] 6. Apc Min/+ Alterations in intestinal barrier function in mice

[0122] Damage to the intestinal mucosal barrier is associated with the enhancement of local inflammation, which is closely related to the occurrence and development of intestinal adenomas. AB / PAS staining and immunohistochemistry were used to observe the changes in the intestinal mucus layer and goblet cell secretory protein Muc2.

[0123] The results showed that Chinese medicine intervention significantly upregulated the expression of Muc2 and increased the thickness of the mucus layer. Figure 7 As shown in A. At the same time, the results also showed that the expression levels of intestinal tight junction proteins Claudin and Zonula occludens-1 (ZO-1) in mice treated with traditional Chinese medicine were significantly upregulated compared with those in the model group, as shown in Figure 7 As shown in B.

[0124] The comprehensive results showed that Chinese medicine intervention has an improving effect on intestinal barrier damage in mice.

[0125] 7. Apc Min/+ Changes in the composition and structure of the intestinal flora in mice

[0126] The effects of traditional Chinese medicine intervention on intestinal bacteria were studied using intestinal flora 16S rRNA sequencing technology.

[0127] The results showed that after the intervention of traditional Chinese medicine, the intestinal flora structure of mice changed significantly, such as Figure 8 As shown in A, at the door level, Apc Min/+ Bacteroidetes and Firmicutes were the most abundant in the intestinal flora of mice. Compared with the model group, Chinese medicine intervention significantly increased the abundance of Verrucomicrobiota (P<0.05) and decreased the abundance of Campilobacterta (P<0.01). Figure 8 As shown in B; Figure 8 Middle C shows the abundance changes of the top 33 differential species between the two groups (sorted by relative abundance), belonging to 16 genera. We found that after Chinese medicine intervention, the abundance of beneficial bacteria such as Akkermansia, Anaerovorax, Parvibacter and Eubacterium_ventriosum_group increased significantly, while the abundance of harmful bacteria such as Alistipes, Christensenellaceae_R-7_group and Helicobacter decreased significantly.

[0128] The comprehensive results show that Chinese medicine intervention has a significant regulatory effect on intestinal flora. We also speculate that these flora may be the key species for Chinese medicine intervention to exert its efficacy.

[0129] 8. Apc Min/+ Correlation between changes in intestinal flora and the number of adenomas in mice

[0130] To further identify specific bacterial species associated with the number of small intestinal adenomas, Spearman correlation analysis was applied to confirm their relationship. Alistipes and Christensenellaceae R-7_ group There was a significant positive correlation between the number of small intestinal adenomas and Akkermansia and Anaerovorax There was a significant negative correlation with the number of small intestinal adenomas ( Fig. 9). At the species level, 5 bacteria were significantly positively correlated with the number of small intestinal adenomas, such as Alistipes Inops and Alistipes sp. cv1, and 3 bacteria were significantly negatively correlated with the number of small intestinal adenomas, such as Akkermansia muciniphila ,like Fig. 9 shown.

[0131] 9. Apc Min/+ Changes in metabolites of intestinal flora in mice

[0132] Recent studies have shown that intestinal flora has an important impact on host health through its metabolites. We used LC-MS / MS to quantitatively detect flora-related metabolites in mouse feces.

[0133] The results showed that compared with the model group, the levels of 16 metabolites changed significantly after Chinese medicine intervention (corrected P<0.05), including 1 amino acid (Pipecolic acid), 1 benzene (ortho-Hydroxyphenylaceticacid), 7 bile acids (bMCA, bUDCA, NorCA, TaMAC / TbMCA, TCA, THDCA, TUDCA), 2 carbohydrates (Rhamnose, Xylose), 1 carnitine (L-Carnitine), 2 fatty acids (DPA, Oleic acid), 1 organic acid (Isocitric acid), and 1 pyridine (Picolinic acid). It can be seen that Chinese medicine intervention mainly affects bile acid (BAs) metabolism. These altered bile acids, including 4 primary BAs (βMCA, NorCA, TaMAC / TbMCA, TCA) and 3 secondary BAs (βUDCA, THDCA, TUDCA), all increased significantly after Chinese medicine intervention, such as Fig.10 shown.

[0134] 10. Apc Min/+ Correlation between fecal metabolites and intestinal flora and the number of intestinal adenomas in mice

[0135] We used Spearman correlation analysis to investigate the relationship between the levels of 16 differential metabolites and the number of small intestinal adenomas.

[0136] The results showed that the levels of βUDCA (r=-0.7295, P=0.0209) and TUDCA (r=-0.6748, P=0.0372) were significantly negatively correlated with the number of small intestinal adenomas. Fig.11 As shown in A.

[0137] In order to further clarify the intestinal flora that is significantly associated with differential bile acids, we further analyzed the relationship between TUDCA, βUDCA and intestinal flora.

[0138] The results showed that TUDCA, βUDCA and Akkermansia There is a significant positive correlation with Alistipes and Christensenellaceae R-7_group There was a significant negative correlation between bUDCA and Anaerovorax, Defluviitaleaceae UCG-011 was significantly positively correlated with Alloprevotella, Helicobacter, Prevotellaceae_NK3B31_group There is a significant negative correlation, such as Fig.11 As shown in B.

[0139] The comprehensive results indicate that Chinese medicine intervention may affect bile acid metabolism, especially the changes in TUDCA and βUDCA, by regulating these specific intestinal flora, thereby affecting the occurrence and development of intestinal adenomas.

[0140] In summary, the pharmacological experimental results show that the Chinese medicine composition of the present invention has an effect on APCs that spontaneously form multiple adenomas. Min/+ It has a significant inhibitory effect on adenoma growth in mice, and is also manifested by improved intestinal mucosal barrier permeability, suppressed adenoma cell proliferation, and reduced intestinal and systemic inflammatory responses. It may affect bile acid metabolism by regulating specific intestinal flora, thereby affecting the occurrence and development of intestinal adenomas.

[0141] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A Chinese medicine composition, characterized in that: The Chinese medicine composition is composed of Herba Epimedii, Scutellariae Barbatae, Herba Tengliae, Coix Seed, Prunus Mume and Cardamomum villosum, wherein the weight proportions of the Chinese medicine composition are: 20-40 parts of Herba Epimedii, 20-40 parts of Scutellariae Barbatae, 20-40 parts of Herba Tengliae, 20-40 parts of Coix Seed, 10-20 parts of Prunus Mume and 5-15 parts of Cardamomum villosum.

2. A Chinese medicine composition according to claim 1, characterized in that: The weight proportions of the traditional Chinese medicine composition are 25-35 parts of Herba Epimedii, 25-35 parts of Scutellariae Barbatae, 25-35 parts of Rhizoma Cibotii, 25-35 parts of Semen Coicis, 13-17 parts of Prunus mume and 8-12 parts of Cardamomum villosum.

3. A Chinese medicine composition according to claim 1, characterized in that: The dosage form of the Chinese medicine composition is water decoction, tablet, granule, capsule, pill and paste.

4. Use of a traditional Chinese medicine composition according to any one of claims 1 to 3 in the preparation of a drug for treating colorectal adenoma.